Research programme: autoimmune disorder therapeutics - Polyneuron Pharmaceuticals

Drug Profile

Research programme: autoimmune disorder therapeutics - Polyneuron Pharmaceuticals

Alternative Names: PN 032; PN 056; PN 1007; PN 1018

Latest Information Update: 04 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Polyneuron Pharmaceuticals
  • Class Glycopeptides; Immunotherapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Motor neuron disease; Peripheral nervous system diseases
  • Research IgA nephropathy; Transplant rejection

Most Recent Events

  • 30 May 2018 Early research in IgA nephropathy in Switzerland (Parenteral) prior to May 2018 (Polyneuron Pharmaceuticals pipeline, May 2018)
  • 30 May 2018 Early research in Transplant rejection in Switzerland (Parenteral) prior to May 2018 (Polyneuron Pharmaceuticals pipeline, May 2018)
  • 15 Jul 2016 Preclinical trials in Peripheral nervous system diseases and Motor neuron disease in Switzerland (Parenteral) (Polyneuron Pharmaceuticals pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top